Isotretinoin (13-cis-retinoic acid; UK POM — Roaccutane, Reticutan)

Isotretinoin (sold in the UK as Roaccutane, Reticutan, and other names) is a strong oral medicine for severe acne. It is UK Prescription-Only — you cannot buy it over the counter or online from any legal UK source. The NHS pathway is GP referral to dermatology; treatment is led by a specialist, with monthly check-ins and blood tests, typically over 4-6 months. The two most important things to know are well-publicised but worth repeating clearly: (1) isotretinoin must NOT be taken during pregnancy — it causes serious harm to a developing baby, so the UK runs a strict Pregnancy Prevention Programme for women of childbearing age (pregnancy tests, two forms of contraception, monthly prescriptions); (2) some people on isotretinoin experience low mood or depression — the 2024 MHRA Drug Safety Update reinforced the need for monitoring, and patient + family + GP awareness is essential. If you or your family notice mood changes during treatment, contact the prescriber. Camden Medicals does NOT stock or sell isotretinoin. This entry exists as a UK-anchored reference for anyone researching the medicine.

Camden Medicals editorial · Last reviewed 6 May 2026 · Next review November 2026

Cross-checked against
NHS
NICE
BNF
EFSA
FSA

Verifera Evidence ReviewCamden evidence review · independently appraised — graded, not guessed.

Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.

Class: Vitamin
Typical daily dose: 0.5-1 mg/kg/day; total cumulative dose target 120-150 mg/kg over 16-24 weeks. Specialist-prescribed.
Top use evidence: Strong

On this page

What it is
How it works

What it is

Isotretinoin is a strong oral form of vitamin A — the same chemical family as topical retinol, but taken as a capsule and reaching the whole body at concentrations far higher than any cream could deliver. It is prescribed by UK dermatologists for severe nodular acne — the kind that leaves deep cysts and scarring, and that hasn't cleared with other treatments.

UK brand names you'll see on a prescription:
- Roaccutane — the original Roche brand, sometimes used as a generic name for the medicine
- Reticutan, Rizuderm — UK generic versions
- Various other generics under the name "isotretinoin"

What the treatment looks like in practice:

- GP first — you start with your GP, who tries first-line treatments (topical creams + oral antibiotics, typically over 8-12 weeks).
- Dermatology referral — if first-line hasn't worked, your GP refers you to a NHS dermatologist.
- Pre-treatment work-up — pregnancy test (for women of childbearing age), liver-function and cholesterol blood tests, mood-history check.
- The course — 4-6 months typically, sometimes longer. Monthly clinic visits with bloods + pregnancy tests. Most people see clearance over the course; for many, the clearance persists for years after stopping.
- Side effects to expect — dry lips, dry skin, dry eyes are universal. Other side effects vary. The prescriber + patient information leaflet walks through what to watch for.

Camden Medicals does NOT stock or sell isotretinoin. We retail oral food supplements and topical cosmetic ingredients; prescription medicines are not within our regulated tier. This entry exists because consumers researching the topical retinol family often encounter isotretinoin in the conversation and deserve a UK-anchored explanation.

At a glance

UK Prescription-Only Medicine. NOT available over the counter, online, or via Camden. The UK pathway is GP referral to dermatology.
For severe acne that has not responded to other treatments. NHS-led specialist treatment under NICE NG198.
PREGNANCY: must not be taken. UK runs a Pregnancy Prevention Programme (pregnancy tests, two forms of contraception, monthly prescriptions) for women of childbearing age. Severe harm to the developing baby is well-established.
MOOD: low mood and depression have been linked to isotretinoin. The 2024 MHRA Drug Safety Update reinforced monitoring. Patient + family + GP awareness is the safety mechanism.
Treatment is typically 4-6 months at a specialist-calculated dose. Most people achieve long-term clearance.
Do NOT use OTC retinol or retinaldehyde alongside isotretinoin — pause for ≥1 month before starting and during the entire course.
Buying isotretinoin online from non-UK sources is illegal and unsafe — it bypasses pregnancy testing and monitoring entirely.

What people use it for

Adults or adolescents with severe nodular acne that has failed first-line treatment
UK NICE NG198 pathway: isotretinoin via specialist dermatology after moderate-to-severe acne has failed topical fixed combinations + oral antibiotics over 8-12 weeks. Treatment course 16-24 weeks at 0.5-1 mg/kg/day; total cumulative dose target 120-150 mg/kg. Long-term remission rates 60-80% in trial populations. Camden does NOT prescribe — UK NHS GP / specialist pathway only. ^[1]
Some evidenceStrong
Women of childbearing potential considering isotretinoin
MHRA Pregnancy Prevention Programme (PPP) is mandatory: pregnancy testing 1 month before / monthly during / 1 month after treatment; 2 forms of contraception (or documented abstinence); monthly prescription cycles. Talk to GP or dermatologist before starting. Severe teratogenicity precedent — pregnancy during treatment is contraindicated. ^[1]
Some evidenceStrong
Patients with mood / depression / suicidal ideation history considering isotretinoin
2024 MHRA Drug Safety Update reinforced monitoring requirements. Talk to GP and consider mental-health input before starting. Patient + family + prescriber awareness of mood-symptom monitoring is the load-bearing safety mechanism. UK NICE NG198 monitoring schedule applies. ^[1]
Some evidenceStrong
Adults wanting to self-supplement isotretinoin without prescription
Not possible legally in the UK — POM Schedule 4 Part I status. Online pharmacy purchases bypass UK MHRA PPP framework and create acute teratogenic + mood-monitoring risk. UK NHS pathway is GP / dermatology specialist; talk to GP for a clinically-supervised route. ^[1]
Some evidenceStrong

How it works

Severe acne happens when the skin's oil glands produce too much sebum, the pores get blocked, and bacteria thrive in the trapped oil — producing the deep, painful nodules that don't respond to topical creams. Isotretinoin works by dramatically reducing how much sebum the oil glands produce — typically by 80-90% within the first 2-3 months of treatment. With far less sebum, the bacteria don't have the substrate they need, and the cycle of acne breaks.

Unlike topical retinol (which works on the surface skin layer and needs to keep being applied), isotretinoin reaches the oil glands themselves and reorganises them — they shrink during treatment and, for many people, stay smaller after the course ends. This is why isotretinoin produces lasting clearance for many people rather than just suppressing acne while you take it.

The pregnancy harm is the same chemistry working in the wrong context. Vitamin-A signalling is essential for normal development of a baby's face, heart, and brain — and isotretinoin at treatment doses overwhelms that signalling, causing severe malformations and miscarriage. This is why the UK Pregnancy Prevention Programme is built around making absolutely sure pregnancy doesn't happen during or just after treatment.

The mood signal is less fully understood. Severe acne itself is associated with depression — the appearance impact + social distress + chronicity. Treatment generally improves mood as the acne clears. But some people experience mood changes that appear linked to the medicine itself, independent of the acne course. The 2024 MHRA update reinforced that prescribers, patients, and families should all know to watch for changes and act early.

Common myths

Myth""You can buy isotretinoin online without prescription.""

RealityNot legally in the UK. POM status. Online-pharmacy purchases bypass MHRA PPP framework — pregnancy + mood-monitoring safety mechanisms inoperative. Acute risk.

Myth""Isotretinoin is just stronger retinol.""

RealityDifferent regulatory tier (POM vs cosmetic), different delivery (systemic vs topical), different effect intensity (sebaceous gland atrophy vs gradual photoaging modulation), different safety framework (PPP vs precautionary topical avoidance). Same retinoid family; vastly different clinical contexts.

Myth""You should pair isotretinoin with topical retinol for faster results.""

RealityCONTRAINDICATED. Systemic isotretinoin already produces high circulating retinoid concentrations; adding topical retinol stacks retinoid-receptor signalling and dramatically increases retinization without proportional benefit. Stop topical retinol / retinaldehyde ≥1 month before isotretinoin and during the entire course. ^[1]

Myth""Isotretinoin causes depression in everyone.""

RealityMood-symptom monitoring is required because some users experience direct mood effects; causality is complex (severe acne itself is associated with depression; resolution is mood-positive; subset of users experience treatment-related mood changes independent of acne course). 2024 MHRA Drug Safety Update reinforced monitoring without re-classifying indication.

What people say online

Isotretinoin is one of the highest-volume search clusters in UK skincare discourse. TikTok hashtags #accutane and #accutanejourney aggregate millions of views. Reddit's r/Accutane and r/AccutaneRecovery are dedicated subreddits. The dominant narratives are: (1) before / after journey content compressed to weeks of treatment in minutes; (2) dry-lips-and-eyes side-effect documentation; (3) mood symptoms posted as personal accounts. UK consumers researching the medication through these channels often encounter US-clinic-centred content that does not map onto the UK MHRA Pregnancy Prevention Programme framework. This section surfaces the discourse without naming individuals and refers each claim to UK authority.

Trending claims

TikTok + Reddit (overseas pharmacy promotion)high visibility
Claim: You can buy isotretinoin online without a prescription
Reality check: Not legally in the UK. Isotretinoin is a Prescription-Only Medicine (POM), Schedule 4 Part I. Online-pharmacy purchases that bypass UK MHRA Pregnancy Prevention Programme create acute teratogenic + mood-monitoring risk. The UK NHS pathway is GP referral to dermatology under NICE NG198. ^[1]
TikTok + Reddithigh visibility
Claim: Isotretinoin definitely causes depression in everyone
Reality check: The evidence is mixed. Sundström 2010 (PMID 21071484) Swedish cohort n=5,756 raises during-treatment SIR to 1.78 for suicide attempt; Jick 2000 (PMID 11030769) UK + Canadian cohort n=7,195 finds RR ~1.0. Severe acne is itself a risk factor for depression. 2024 MHRA Drug Safety Update reinforced monitoring requirements. Patient + family + prescriber awareness is the load-bearing safety mechanism. ^[6,7]
TikTok (skincare optimisation content)medium visibility
Claim: Stack isotretinoin with topical retinol for faster results
Reality check: CONTRAINDICATED. Systemic isotretinoin already produces circulating retinoic-acid concentrations 100-1000× higher than achievable with topical retinoid application; adding topical retinoids stacks receptor signalling without proportional benefit and dramatically increases retinization. Stop topical retinoids ≥1 month before isotretinoin and during the entire course; resume ≥1 month after finishing. ^[1]
TikTok + r/SkincareAddictionhigh visibility
Claim: Low-dose isotretinoin / micro-dose accutane is the safer alternative
Reality check: Low-dose protocols (e.g. 0.25-0.4 mg/kg/day vs standard 0.5-1 mg/kg/day) have some trial evidence (Simpson 2011 systematic review, PMID 22074369, references a Korean RCT n=60 suggesting better long-term outcomes with reduced side effects in moderate acne) but the MHRA Pregnancy Prevention Programme + monthly monitoring requirements apply at any dose. Specialist prescriber decides on the protocol; not a consumer-self-prescribed protocol. ^[8]

Where the conversation lives

TikTok hashtags: #accutane, #accutanejourney, #accutanediaries, #isotretinoin
Reddit subs: r/Accutane, r/AccutaneRecovery, r/AccutaneUK, r/SkincareAddiction
Forums: Acne.org community, RealSelf isotretinoin discussions

Questions people are searching

Will I get depressed on accutane?
How dry are the side effects really?
Can I drink alcohol on accutane?
Does accutane cause inflammatory bowel disease?
How long after stopping accutane can I get pregnant?

Who drives the discourse: The discourse is driven by three influencer classes: dermatology doctor creators (most evidence-anchored on UK NICE NG198 + MHRA PPP context); patient journey-vlogger creators (highest reach, narratively powerful but often US-clinic-centred); and skincare-influencer creators (variable evidence-anchoring, sometimes promoting low-dose protocols outside specialist framing). Verifera editorial does not name individuals.

Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.

Common online questions

Synthesised from the questions UK shoppers most often ask online about Isotretinoin (13-cis-retinoic acid; UK POM — Roaccutane, Reticutan). Each answer is editorial and links to its evidence in the Sources list below.

Can I buy Roaccutane online without seeing a dermatologist?

Not legally in the UK. POM Schedule 4 Part I. Online-pharmacy purchases bypass MHRA Pregnancy Prevention Programme and create acute teratogenic + mood-monitoring risk. UK NHS pathway: GP referral to dermatology. ^[1]

How does the Pregnancy Prevention Programme work?

For women of childbearing potential: pregnancy testing 1 month before / monthly during / 1 month after; 2 forms of contraception (or documented abstinence); monthly prescription cycles with prescriber documentation. UK MHRA PPP framework. ^[1]

Should I stop my topical retinol while on isotretinoin?

Yes — and starting ≥1 month before. Topical retinol stacks systemic retinoid signalling and increases retinization without proportional benefit. Resume topical retinol ≥1 month after finishing isotretinoin course.

What about the depression risk?

2024 MHRA Drug Safety Update reinforced existing monitoring requirements. Patient + family + prescriber awareness is the load-bearing safety mechanism. Stop and contact prescriber if mood symptoms emerge. Camden encourages anyone with mental-health history to discuss with both GP and dermatologist before starting. ^[1]

UK regulatory landscape

UK regulatory tier: Prescription-Only Medicine (POM)

Isotretinoin is a UK Prescription-Only Medicine (POM) under Schedule 4 Part I of the MHRA Human Medicines Regulations 2012, with marketing authorisations held by Roche (Roaccutane®) and multiple UK generic manufacturers (Reticutan®, Rizuderm®, and others). Prescribing is specialist-led — UK consultant dermatologist or specialist-GP supervision per NICE NG198. The MHRA Pregnancy Prevention Programme (PPP) is mandatory for all women of childbearing potential and is a load-bearing safety framework reflecting the severe teratogenicity precedent. The 2024 MHRA Drug Safety Update reinforced mood / depression / suicidality monitoring requirements following coroner- investigation cases.

What crosses the tier

Condition	Crosses to
Online-pharmacy sale without prescription (often EU / overseas-sourced)	Illegal under UK Human Medicines Regulations 2012. Bypasses MHRA PPP framework — acute teratogenic + mood-monitoring risk.
Marketing as a cosmetic or skincare product	Illegal under MHRA Human Medicines Regulations 2012. Isotretinoin is a POM, not a cosmetic.
Prescription outside specialist dermatology supervision (where local commissioning requires)	Outside NICE NG198 pathway; clinical-governance concern. Specialist-GP supervision is acceptable under shared-care agreements where commissioned.

Permitted claims

Marketing of isotretinoin to consumers is severely restricted under the UK Human Medicines Regulations 2012 (POMs cannot be advertised to the public). Healthcare-professional information is governed by the Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), and MHRA Drug Safety Update bulletins. The UK NHS pathway is GP referral to dermatology under NICE NG198 + acne CKS.

Cross-jurisdiction note

US isotretinoin regulation operates under the iPLEDGE Programme (functional equivalent of the UK MHRA PPP) but with different operational details. EU regulation since 2018 mandates the Pregnancy Prevention Programme in all member states. UK retains the PPP framework as MHRA post-EU-exit regulator. UK consumers should not assume US iPLEDGE materials are interchangeable with UK MHRA PPP requirements.

UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.

🔬 Camden’s evidence review

The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.

Severe nodular acne — long-term remission
StrongEvidencestrong
Multiple RCTs and cohort studies support isotretinoin for severe nodular acne with 60-80% long-term remission at standard cumulative-dose protocols. The Cochrane review (Costa 2018) pooled 31 RCTs (3836 participants) of oral isotretinoin for acne. UK NICE NG198 pathway. ^[1,9]
Pregnancy retinoid embryopathy
StrongEvidencestrong
Severe teratogenicity precedent established (Lammer 1985 NEJM: 154 exposed pregnancies, RR 25.6 for major malformations; Dai 1992: 47% of births malformed). MHRA Pregnancy Prevention Programme is mandatory. ^[1,10,11]
Mood / depression / suicidality
MixedEvidencemixed
2024 MHRA Drug Safety Update reinforced monitoring. Causality complex; conservative monitoring posture universal. ^[1]

Effect matrix — per-condition evidence

Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.

Outcome	Population	Dose	Duration	Evidence	Direction	Sources
Severe nodular acne (long-term remission)	adults	0.5–1 mg	16–24 wk	StrongEvidencestrong	improvement	PMID 22074369 PMID 30484286
UK NICE NG198 specialist-dermatology pathway after first-line topical + oral antibiotic failure. Standard cumulative-dose target 120-150 mg/kg over 16-24 weeks at 0.5-1 mg/kg/day. 60-80% sustained long-term remission rates in trial populations. Dose expressed as mg/kg/day not absolute mg — schema dose_unit "mg" is a convention approximation pending A1 extension.
Acne scarring prevention	adults	0.5–1 mg	16–24 wk	ModerateEvidencemoderate	improvement	—
Indirect benefit downstream of severe-acne clearance. UK NICE NG198 notes scar-revision is a separate aesthetic-medicine context, but achieving early severe-acne control reduces ongoing scar formation. Moderate evidence as outcome is observational rather than RCT primary endpoint.
Persistent moderate acne (low-dose protocol)	adults	0.25–0.4 mg	16–32 wk	ModerateEvidencemoderate	improvement	PMID 22074369 PMID 33085149 PMID 30484286 PMID 21114478
Low-dose protocol (0.25-0.4 mg/kg/day) for moderate acne refractory to first-line. Evidence base is multi-trial: the Cochrane 2018 review pooled 14 dose/regimen-comparison RCTs (906 participants), including a continuous-low-dose vs conventional-dose RCT in moderate acne; a dedicated low-dose systematic review (Sadeghzadeh-Bazargan 2020) summarised 15 clinical studies; and Simpson 2011 summarises a Korean low-dose RCT (n=60) suggesting better long-term outcomes with reduced side effects vs standard-dose. Specialist-prescribed; MHRA PPP applies at any dose.
Mood disorders / depression / suicidality risk	adults	0.5–1 mg	16–24 wk	ModerateEvidencemoderate	mixed	PMID 21071484 PMID 11030769
Sundström 2010 (n=5,756, Swedish cohort) SIR 1.78 for suicide attempt during treatment + 6 months; Jick 2000 (n=7,195, UK + Canadian cohort) RR ~1.0 (no signal). 2024 MHRA Drug Safety Update reinforced monitoring without re-classifying indication. Conservative monitoring posture; severe acne itself is a depression risk factor — causality complex. Patient + family + prescriber awareness is the load-bearing safety mechanism.
Foetal retinoid embryopathy (teratogenicity)	pregnancy	0.5–1 mg	0 wk	StrongEvidencestrong	decrement	PMID 3162101 PMID 1597546
CONTRAINDICATED in pregnancy. Severe human teratogen — exposure produces retinoid embryopathy (craniofacial, cardiovascular, CNS, thymic malformations + high spontaneous abortion rate). UK MHRA Pregnancy Prevention Programme (PPP) is mandatory for women of childbearing potential: pregnancy testing 1 month before / monthly during / 1 month after treatment; 2 forms of contraception (or documented abstinence); monthly prescription cycles. Schema enum limitation — `decrement` used here as proxy for "harmful"; teratogenicity is treatment-caused harm where the outcome IS the harm, not a worsened-trial-endpoint pattern. See SCHEMA-EXTENSION-REQUESTS.md §A2.

Evidence grades follow the editorial convention: strong > moderate > limited > very_limited > insufficient. Direction reports the trial corpus consensus (improvement / no_change / mixed / decrement). Schema cross-emitted at MedicalSubstance.relevantClinicalCondition[].

Clinical literature review

The isotretinoin literature spans 40+ years since its 1982 introduction. Long-term-remission evidence in severe nodular acne is strong (60-80% sustained remission at standard cumulative-dose protocols — UK NICE NG198 places isotretinoin as the specialist-led option after first-line therapy failure). The mood / depression / suicidality signal has been investigated across multiple large cohort studies with mixed findings — Sundström et al. 2010 (BMJ, PMID 21071484, Swedish cohort n=5,756) reported a raised standardised incidence ratio for suicide attempt during and within 6 months after treatment (SIR 1.78), while also documenting raised pre-treatment risk (SIR 1.57) which complicates causal attribution. Jick et al. 2000 (Arch Dermatol, PMID 11030769, Canadian + UK cohort n=7,195) reported no association (RR ~1.0) using a different methodology comparing to oral-antibiotic controls. The 2024 MHRA Drug Safety Update reinforced existing monitoring requirements without re-classifying the indication. UK regulatory framework (Pregnancy Prevention Programme + monthly prescription cycles + monthly liver-function + lipid + pregnancy testing) reflects the severe teratogenicity precedent and contemporary mood-monitoring posture.

Key trials

Sundström A et al. · 2010 · BMJ · PMID 21071484
Design: Retrospective cohort study (named-patient register linkage) · n = 5756 · Duration: 17,197 person-years pre-treatment + 2,905 during + 87,120 post (15-year follow-up)
Finding: Standardised incidence ratio (SIR) for attempted suicide was 1.57 (95% CI 0.86-2.63) in the year before treatment, 1.78 (1.04-2.85) during treatment and up to 6 months after, and 1.04 (0.74-1.43) three years after treatment. Number-needed- to-harm was 2,300 6-month treatments per year for one additional first suicide attempt. 71% of patients who made their first attempt within 6 months after treatment made a new attempt or completed suicide during follow-up.
Relevance: Largest UK-relevant European cohort with linked outcome data. Documents both a treatment-window signal and pre-existing risk. Authors conclude monitoring should extend to 1 year after treatment ends; severe-acne history is itself associated with raised attempt risk.
Jick SS et al. · 2000 · Arch Dermatol · PMID 11030769
Design: Large population-based cohort studies — Canadian Saskatchewan Health Database + UK General Practice Research Database · n = 7195 · Duration: 6 months to 5 years pre + ≥12 months post
Finding: Relative risk for newly diagnosed depression or psychosis when comparing isotretinoin users vs oral-antibiotic users was approximately 1.0 across both data sources. Relative risk for suicide / attempted suicide comparing isotretinoin exposure with non-exposure was 0.9 (95% CI 0.3-2.4). No evidence of increased psychiatric risk.
Relevance: Earlier large-cohort study using oral-antibiotic-controlled design (different from Sundström's general-population comparator). Mixed conclusions between trials reflect the underlying causal complexity — severe acne is itself a risk factor; treatment-effect attribution requires careful comparator choice.
Simpson RC et al. · 2011 · Clin Exp Dermatol · PMID 22074369
Design: Systematic review of acne RCTs + cohort 2010-11
Finding: Summarises the Sundström cohort plus a Korean low-dose isotretinoin RCT (n=60) suggesting lower-dose protocols may give a better long-term outcome with reduced side effects in moderate acne. Concludes patients with severe acne with a history of attempted suicide should not automatically be refused isotretinoin.
Relevance: UK Centre of Evidence Based Dermatology (Nottingham) analysis — informs UK NICE NG198 contextual guidance on low-dose protocols + mood-history individualised assessment.
Lee JW et al. · 2011 · Br J Dermatol · PMID 21114478
Design: Randomised controlled trial — low-dose vs conventional-dose isotretinoin, moderate acne · n = 60
Finding: Low-dose isotretinoin (0.25-0.4 mg/kg/day) gave comparable efficacy to conventional dosing (0.5-0.7 mg/kg/day) for moderate acne with fewer adverse effects over the course — the Korean RCT summarised by Simpson 2011 above.
Relevance: Primary-source RCT grounding the effect_matrix 'persistent moderate acne (low-dose protocol)' row; basis for the low-dose protocol option in UK practice.

Systematic reviews

pmid:22074369
Simpson 2011 systematic-review summary of 2010-11 acne RCTs including the Sundström 2010 cohort and a Korean low-dose RCT.
pmid:30484286
Costa CS et al. 2018 — Cochrane review "Oral isotretinoin for acne", 31 RCTs (3836 participants). The dose/regimen-comparison subset comprised 14 RCTs (906 participants), including a continuous-low-dose vs conventional-dose RCT in moderate acne.
pmid:33085149
Sadeghzadeh-Bazargan 2020 — systematic review of low-dose isotretinoin for acne vulgaris (15 included clinical studies): low daily doses (0.1-0.3 mg/kg) can be effective with fewer dose-dependent side effects.

Evidence quality summary

Long-term remission in severe nodular acne — HIGH certainty (NICE NG198, multiple RCTs + cohort studies, sustained 60-80% remission rates at cumulative-dose protocols). Pregnancy teratogenicity — HIGH certainty (established human teratogen precedent, MHRA PPP framework reflects this). Mood / depression / suicidality association — MIXED certainty (Sundström 2010 raises during-treatment SIR; Jick 2000 finds RR ~1.0; contemporary 2024 MHRA Drug Safety Update reinforces monitoring without changing the licensed indication). The mixed signal supports conservative monitoring rather than treatment withholding.

Known gaps

No head-to-head RCTs of standard-dose vs low-dose vs micro-dose isotretinoin in moderate acne (most data is single-arm cohort).
Long-term (>5 year) data on inflammatory bowel disease association remains debated; no definitive resolution.
Limited UK-specific contemporary trial data — most cohort evidence is Scandinavian / North American.
No RCT evidence on optimal mood-monitoring frequency post-2024 MHRA Drug Safety Update.
Pregnancy-prevention compliance under the MHRA PPP varies in real-world audit data; pharmacovigilance gap.

This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.

Safety

Isotretinoin is a UK PRESCRIPTION-ONLY MEDICINE for severe nodular acne that has failed other treatments. Mandatory MHRA Pregnancy Prevention Programme. 2024 MHRA Drug Safety Update reinforced mood / depression / suicidality monitoring. UK NHS pathway only.

Talk to your pharmacist or GP first if you:

You have severe nodular acne and want to discuss isotretinoin — GP referral to dermatology.
You are taking isotretinoin and develop mood / depression symptoms — contact prescriber immediately.
You are pregnant or become pregnant during isotretinoin treatment — contact prescriber immediately and stop treatment.
You take any oral retinoid and want to start topical retinol — do NOT stack; talk to dermatologist first.

Common side effects: Dry skin / lips / eyes (universal). Photosensitivity. Lipid profile changes. Mood symptoms in subset. Very rare: pseudotumor cerebri, severe skin reactions, hepatotoxicity.

Pregnancy and breastfeeding

CONTRAINDICATED. Isotretinoin is a severe human teratogen — pregnancy exposure produces retinoid embryopathy (craniofacial, cardiovascular, central-nervous-system, and thymic malformations, with high spontaneous abortion rate). The UK MHRA Pregnancy Prevention Programme (PPP) is MANDATORY for all women of childbearing potential — pregnancy testing 1 month before, monthly during, and 1 month after treatment; 2 forms of contraception (or documented abstinence); monthly prescription cycles. If pregnancy occurs during treatment, stop immediately and contact your prescriber. Talk to your midwife or GP about preconception planning if you have finished treatment and are considering pregnancy.

CONTRAINDICATED. Isotretinoin is excreted in breast milk and carries the same teratogenic / retinoid-toxicity profile. The UK PPP framework extends pregnancy testing for 1 month after treatment ends to ensure conception did not occur in the wash-out window. Talk to your midwife or GP for breastfeeding- compatible alternatives if severe acne is the indication.

Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.

More clinical detail (for clinicians and informed readers)

Contraindications

Pregnancy and breastfeeding (severe teratogenicity).
Concurrent tetracycline antibiotics (pseudotumor cerebri risk).
Concurrent topical retinol / retinaldehyde / tretinoin / adapalene / tazarotene.
Severe hepatic impairment.
Severe hyperlipidaemia.
Hypervitaminosis A.
Hypersensitivity to retinoids or excipients (peanut / soy excipient warnings on some preparations).

Drug interactions

Tetracycline antibiotics (doxycycline, lymecycline, minocycline) · high
Effect: Risk of pseudotumor cerebri (idiopathic intracranial hypertension) — both isotretinoin and tetracyclines independently raise intracranial pressure; concurrent use is CONTRAINDICATED.
Mechanism: Additive effects on cerebrospinal-fluid dynamics; clinical precedent of pseudotumor cerebri reports under combination use established in the dermatology literature.
Action: Tell your dermatologist and your GP if you are on oral tetracycline antibiotics for any reason — the antibiotic course must complete and clear before isotretinoin starts.
Source: BNF isotretinoin + tetracycline monographs
Topical retinoids (tretinoin, adapalene, tazarotene, retinol, retinal) · medium
Effect: Additive retinoid-receptor signalling stacks retinization without proportional benefit. Stop topical retinoids ≥1 month before isotretinoin and during the entire course; resume ≥1 month after finishing.
Mechanism: Systemic isotretinoin already produces circulating retinoic- acid concentrations 100-1000× higher than achievable topically; concurrent topical retinoid is redundant and amplifies irritation.
Action: Talk to your dermatologist about the timing — pause topical retinoids ≥1 month before isotretinoin starts.
Source: Camden retinol entry + clinic protocols
Oral vitamin A supplements (high-dose retinyl palmitate) · high
Effect: Additive systemic vitamin A load risks hypervitaminosis A (hepatotoxicity, raised intracranial pressure, teratogenic load). CONTRAINDICATED during isotretinoin course; standard NRV-tier multivitamins also typically paused.
Mechanism: Both contribute to circulating retinol / retinoid pool; additive at the metabolic and toxicity level.
Action: Tell your dermatologist about any vitamin A or multivitamin you take; the prescriber will advise on pausing during the treatment course.
Source: BNF isotretinoin + EFSA vitamin A UL
Hormonal contraception (oral microsphere progestogen-only pill) · high
Effect: Some progestogen-only formulations may have reduced contraceptive effectiveness in the isotretinoin context. The UK MHRA Pregnancy Prevention Programme requires 2 forms of contraception (or documented abstinence) regardless of single-method effectiveness assumptions.
Mechanism: Mechanism uncertain; precautionary doubling reflects severe teratogenicity precedent.
Action: Talk to your dermatologist and your GP about MHRA PPP-compliant contraceptive combinations.
Source: MHRA Pregnancy Prevention Programme
St John's Wort (Hypericum perforatum, traditional herbal preparations) · medium
Effect: CYP3A4 induction may reduce isotretinoin levels; concurrent use should be avoided.
Mechanism: Hyperforin component induces CYP3A4 hepatic enzyme; isotretinoin clearance accelerates.
Action: Tell your dermatologist and pharmacist about any herbal or supplement use before starting isotretinoin.
Source: BNF interactions + Camden st-johns-wort entry
Alcohol (regular or heavy intake) · medium
Effect: Increased hepatotoxicity risk during isotretinoin course; moderation or abstention is the conventional UK clinical recommendation.
Mechanism: Both place metabolic load on hepatic CYP enzymes; combined hepatic stress raises ALT / AST.
Action: Talk to your dermatologist about safe alcohol limits during treatment — monthly liver-function tests are part of standard UK monitoring.
Source: NICE NG198 + BNF isotretinoin

Tell your prescriber if you take any of these combinations. This is not personalised advice.

This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.

Common side effects

Dry skin, dry lips (cheilitis), dry eyes — universal.
Photosensitivity.
Lipid profile changes (elevated cholesterol, triglycerides).
Headache.
Joint / muscle aches.
Nosebleeds (epistaxis).

Rare side effects

Mood / depression symptoms — see 2024 MHRA Drug Safety Update.
Pseudotumor cerebri (idiopathic intracranial hypertension) — particularly with concurrent tetracycline antibiotic.
Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis — rare).
Hepatotoxicity — monthly liver-function tests required.
Inflammatory bowel disease — debated association.
Hearing impairment / tinnitus (rare).
Severe teratogenicity in pregnancy.

How to take it

Typical supplemental range: 0.5-1 mg/kg/day; total cumulative dose target 120-150 mg/kg over 16-24 weeks. Specialist-prescribed.
Timing: With food (improves absorption — fat-soluble).

How to spot quality

Look for

UK MHRA marketing authorisation number on the pack.
UK pharmacist dispensed via prescription.
PPP documentation if women of childbearing potential.

Red flags

Online purchases without UK prescription — POM status.
Importation from EU / US without prescription.
Marketing as a cosmetic product — illegal under MHRA Human Medicines Regulations 2012.

Commonly combined with

Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.

Vitamin C topical (L-ascorbic acid + ester derivatives)

Limited evidence

During-treatment antioxidant adjunct compatible with isotretinoin (unlike topical retinol).

Topical vitamin C is compatible during isotretinoin course (different regulatory + receptor mechanism — antioxidant + tyrosinase inhibition + procollagen cofactor vs systemic retinoid-receptor signalling). Topical retinol IS contraindicated.

Evidence: During-treatment compatible adjunct; not directly trialled with isotretinoin.

Doses studied: AM during isotretinoin course: vitamin C topical 10-20% + sunscreen. Photosensitivity-protection layered.

Niacinamide (Topical, Vitamin B3 amide form)

Limited evidence

During-treatment barrier-rebuild adjunct. Compatible with isotretinoin (unlike topical retinol).

Niacinamide ceramide / FFA synthesis support buffers isotretinoin-induced barrier disruption. Universal compatible during-treatment adjunct.

Evidence: During-treatment compatible adjunct.

Doses studied: AM and PM during isotretinoin course: 5% niacinamide + ceramide moisturiser.

Methyl Folate (5-Methyltetrahydrofolate)

Strong evidence

Post-treatment preconception planning — women of childbearing potential ending isotretinoin who plan pregnancy need preconception folate. Direct combination is NOT during-treatment but post-treatment planning.

After completing isotretinoin course, MHRA PPP recommends 1 month wash-out before contraception cessation; preconception folate (400 µg/day, methyl-folate for MTHFR-variant individuals) supports neural-tube-defect prevention from preconception through 12 weeks gestation.

Evidence: UK NHS preconception folate evidence is strong; isotretinoin sequencing follows MHRA PPP wash-out. ^[12,1]

Doses studied: Post-isotretinoin: 1 month wash-out → preconception folate 400 µg/day → planned conception per UK NHS pathway.

Pregnancy considerations apply

Vitamin A (retinol and provitamin-A carotenoids)

Strong evidence

CONTRAINDICATION-LEVEL pairing — concurrent oral high-dose vitamin A supplements are contraindicated during isotretinoin course (additive systemic vitamin A load).

Both contribute to systemic vitamin A load. Concurrent administration risks hypervitaminosis A. Standard Camden vitamin-a NRV-tier supplementation may need to be paused during isotretinoin course — discuss with prescriber.

Evidence: CONTRAINDICATION. Talk to prescriber if you take any oral vitamin A or retinyl-containing multivitamin. ^[13,1]

Doses studied: DO NOT combine. Pause vitamin A supplements during isotretinoin course.

Pregnancy considerations applyLiver function — caution

Verifera™ editorial perspective

Why it matters. Isotretinoin is the most-discussed acne medication on TikTok and r/AccutaneRecovery, despite being a UK Prescription-Only Medicine that is not consumer-accessible without a specialist prescriber. The Verifera editorial position is that this entry must be unmistakably framed as a POM clinical reference — not a "supplement comparison". The 2024 MHRA Drug Safety Update on mood + depression + suicidality monitoring is the load-bearing contemporary context; the MHRA Pregnancy Prevention Programme is the load-bearing teratogenicity-prevention framework. Both are NHS / specialist-prescriber territory.

Where Camden lands. Camden Medicals does NOT stock or sell isotretinoin and does NOT prescribe. Camden's commercial scope is oral food supplements + topical cosmetic ingredients. This entry exists as a UK-regulatory-anchored reference so consumers researching the systemic-retinoid family alongside topical retinol / retinaldehyde understand the regulatory distinction between tiers.

If you want to explore further. For a UK consumer considering isotretinoin: the appropriate pathway is GP referral to dermatology under the NICE NG198 acne pathway. The NHS isotretinoin medicines page covers what to expect during treatment. For mood-monitoring questions, the 2024 MHRA Drug Safety Update is the contemporary reference. Talk to your GP about UK NHS referral routes.

How this entry was researched

Authoritative sources consulted:

NICE NG198 acne vulgaris guideline
NICE CKS acne vulgaris
NHS isotretinoin medicines page
BNF isotretinoin monograph
MHRA Drug Safety Update (2024) on isotretinoin mood / depression / suicidality
MHRA Pregnancy Prevention Programme materials
NHS preconception planning + folate supplementation guidance
PubMed (via E-utilities MCP)

PubMed search terms:

isotretinoin depression suicide
isotretinoin acne vulgaris cohort suicide attempt
isotretinoin systematic review depression psychiatric

Literature search date: 2026-05-11

Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.